CRSP
Crispr Therapeutics Ag
$55.56
Earnings Summary
Revenue | $200Mn |
Net Profits | $89.35Mn |
Net Profit Margins | 44.67% |
Highlights
Crispr Therapeutics Ag’s revenue jumped 3333233.33% since last year same period to $200Mn in the Q4 2023. On a quarterly growth basis, Crispr Therapeutics Ag has generated +Inf% jump in its revenue since last 3-months.
Crispr Therapeutics Ag’s net profit jumped 180.8% since last year same period to $89.35Mn in the Q4 2023. On a quarterly growth basis, Crispr Therapeutics Ag has generated 179.67% jump in its net profits since last 3-months.
Crispr Therapeutics Ag’s net profit margin jumped 100% since last year same period to 44.67% in the Q4 2023. On a quarterly growth basis, Crispr Therapeutics Ag has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Crispr Therapeutics Ag post its latest quarter earnings
EPS Estimate Current Quarter | -1.36 |
EPS Estimate Current Year | -1.36 |
Highlights
Crispr Therapeutics Ag’s earning per share (EPS) estimates for the current quarter stand at -1.36 - a -1842.86% fall from last quarter’s estimates.
Crispr Therapeutics Ag’s earning per share (EPS) estimates for the current year stand at -1.36.
Key Ratios
Key ratios of the Crispr Therapeutics Ag post its Q1 2024 earnings
Earning Per Share (EPS) | 0 |
Highlights
Crispr Therapeutics Ag’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2024. This indicates that the Crispr Therapeutics Ag has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-05-06 | -1.36 | 0 | 100% |
₹0 US Stocks a/c Opening Fee